|
Gene: NT5C |
Gene summary for NT5C |
Gene summary. |
Gene information | Species | Human | Gene symbol | NT5C | Gene ID | 30833 |
Gene name | 5', 3'-nucleotidase, cytosolic | |
Gene Alias | DNT | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0000255 | UniProtAcc | Q8TCD5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
30833 | NT5C | LZE2D | Human | Esophagus | HGIN | 3.51e-04 | 4.29e-01 | 0.0642 |
30833 | NT5C | LZE2T | Human | Esophagus | ESCC | 1.15e-06 | 9.43e-01 | 0.082 |
30833 | NT5C | LZE4T | Human | Esophagus | ESCC | 1.78e-31 | 9.27e-01 | 0.0811 |
30833 | NT5C | LZE7T | Human | Esophagus | ESCC | 1.71e-05 | 5.30e-01 | 0.0667 |
30833 | NT5C | LZE8T | Human | Esophagus | ESCC | 2.34e-02 | -2.32e-02 | 0.067 |
30833 | NT5C | LZE20T | Human | Esophagus | ESCC | 1.12e-10 | 4.21e-01 | 0.0662 |
30833 | NT5C | LZE21D1 | Human | Esophagus | HGIN | 5.88e-07 | 8.64e-01 | 0.0632 |
30833 | NT5C | LZE22D1 | Human | Esophagus | HGIN | 2.96e-11 | 6.48e-01 | 0.0595 |
30833 | NT5C | LZE22T | Human | Esophagus | ESCC | 5.80e-10 | 9.59e-01 | 0.068 |
30833 | NT5C | LZE24T | Human | Esophagus | ESCC | 5.71e-41 | 1.26e+00 | 0.0596 |
30833 | NT5C | LZE22D3 | Human | Esophagus | HGIN | 2.10e-07 | 4.96e-01 | 0.0653 |
30833 | NT5C | LZE21T | Human | Esophagus | ESCC | 1.36e-13 | 1.11e+00 | 0.0655 |
30833 | NT5C | P1T-E | Human | Esophagus | ESCC | 1.36e-15 | 8.33e-01 | 0.0875 |
30833 | NT5C | P2T-E | Human | Esophagus | ESCC | 2.35e-55 | 9.43e-01 | 0.1177 |
30833 | NT5C | P4T-E | Human | Esophagus | ESCC | 1.01e-50 | 1.14e+00 | 0.1323 |
30833 | NT5C | P5T-E | Human | Esophagus | ESCC | 6.49e-34 | 6.79e-01 | 0.1327 |
30833 | NT5C | P8T-E | Human | Esophagus | ESCC | 2.36e-63 | 1.05e+00 | 0.0889 |
30833 | NT5C | P9T-E | Human | Esophagus | ESCC | 2.34e-55 | 1.26e+00 | 0.1131 |
30833 | NT5C | P10T-E | Human | Esophagus | ESCC | 1.34e-97 | 1.56e+00 | 0.116 |
30833 | NT5C | P11T-E | Human | Esophagus | ESCC | 7.35e-33 | 1.78e+00 | 0.1426 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000028811 | Liver | Cirrhotic | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 26/4634 | 56/18723 | 3.40e-04 | 2.91e-03 | 26 |
GO:0009223 | Liver | Cirrhotic | pyrimidine deoxyribonucleotide catabolic process | 12/4634 | 19/18723 | 4.35e-04 | 3.55e-03 | 12 |
GO:00091622 | Liver | Cirrhotic | deoxyribonucleoside monophosphate metabolic process | 13/4634 | 23/18723 | 1.12e-03 | 7.70e-03 | 13 |
GO:00091251 | Liver | Cirrhotic | nucleoside monophosphate catabolic process | 11/4634 | 18/18723 | 1.13e-03 | 7.73e-03 | 11 |
GO:0006244 | Liver | Cirrhotic | pyrimidine nucleotide catabolic process | 12/4634 | 21/18723 | 1.53e-03 | 9.98e-03 | 12 |
GO:001631111 | Liver | Cirrhotic | dephosphorylation | 130/4634 | 417/18723 | 1.58e-03 | 1.03e-02 | 130 |
GO:00091581 | Liver | Cirrhotic | ribonucleoside monophosphate catabolic process | 9/4634 | 14/18723 | 1.99e-03 | 1.23e-02 | 9 |
GO:0009159 | Liver | Cirrhotic | deoxyribonucleoside monophosphate catabolic process | 9/4634 | 14/18723 | 1.99e-03 | 1.23e-02 | 9 |
GO:0009176 | Liver | Cirrhotic | pyrimidine deoxyribonucleoside monophosphate metabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0009129 | Liver | Cirrhotic | pyrimidine nucleoside monophosphate metabolic process | 11/4634 | 20/18723 | 3.61e-03 | 1.99e-02 | 11 |
GO:0042278 | Liver | Cirrhotic | purine nucleoside metabolic process | 13/4634 | 26/18723 | 4.72e-03 | 2.48e-02 | 13 |
GO:0009116 | Liver | Cirrhotic | nucleoside metabolic process | 25/4634 | 62/18723 | 4.90e-03 | 2.56e-02 | 25 |
GO:0009218 | Liver | Cirrhotic | pyrimidine ribonucleotide metabolic process | 14/4634 | 29/18723 | 5.09e-03 | 2.62e-02 | 14 |
GO:0009261 | Liver | Cirrhotic | ribonucleotide catabolic process | 20/4634 | 47/18723 | 5.57e-03 | 2.82e-02 | 20 |
GO:0051607 | Liver | Cirrhotic | defense response to virus | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:0140546 | Liver | Cirrhotic | defense response to symbiont | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:0000291 | Liver | Cirrhotic | nuclear-transcribed mRNA catabolic process, exonucleolytic | 10/4634 | 19/18723 | 8.23e-03 | 3.83e-02 | 10 |
GO:00464341 | Liver | Cirrhotic | organophosphate catabolic process | 52/4634 | 155/18723 | 8.42e-03 | 3.91e-02 | 52 |
GO:0009173 | Liver | Cirrhotic | pyrimidine ribonucleoside monophosphate metabolic process | 8/4634 | 14/18723 | 9.65e-03 | 4.35e-02 | 8 |
GO:0046049 | Liver | Cirrhotic | UMP metabolic process | 8/4634 | 14/18723 | 9.65e-03 | 4.35e-02 | 8 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024031 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NT5C | insertion | Frame_Shift_Ins | novel | c.565_566insCTCACGCCTATAATCCCAGCACTTTGGGA | p.Glu189AlafsTer13 | p.E189Afs*13 | Q8TCD5 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
NT5C | SNV | Missense_Mutation | rs146917283 | c.272C>T | p.Pro91Leu | p.P91L | Q8TCD5 | protein_coding | tolerated(0.06) | benign(0.085) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NT5C | SNV | Missense_Mutation | c.395N>T | p.Arg132Met | p.R132M | Q8TCD5 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
NT5C | SNV | Missense_Mutation | c.305T>C | p.Leu102Pro | p.L102P | Q8TCD5 | protein_coding | deleterious(0.01) | benign(0.051) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
NT5C | SNV | Missense_Mutation | novel | c.445N>T | p.Val149Phe | p.V149F | Q8TCD5 | protein_coding | deleterious(0.01) | benign(0.225) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NT5C | SNV | Missense_Mutation | c.226N>T | p.Pro76Ser | p.P76S | Q8TCD5 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NT5C | SNV | Missense_Mutation | novel | c.191N>C | p.Val64Ala | p.V64A | Q8TCD5 | protein_coding | deleterious(0.02) | benign(0.272) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NT5C | SNV | Missense_Mutation | rs576379965 | c.478C>T | p.His160Tyr | p.H160Y | Q8TCD5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NT5C | SNV | Missense_Mutation | novel | c.524N>T | p.Pro175Leu | p.P175L | Q8TCD5 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
NT5C | SNV | Missense_Mutation | novel | c.598N>T | p.Arg200Trp | p.R200W | Q8TCD5 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
30833 | NT5C | ENZYME | lamivudine | LAMIVUDINE | ||
30833 | NT5C | ENZYME | gemcitabine | GEMCITABINE | 25162786 |
Page: 1 |